Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF35700 in Treatment-Resistant Schizophrenia
NCT02717195Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Apr 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of lu af35700 in schizophrenia (3 arms), sponsored by Lundbeck. Primary endpoint: Change From Randomization to Week 10 in Positive and Negative Syndrome Scale (PANSS) Total Score. Started Apr 2016; status: completed.
02
Drugs
lu af35700
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02717195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02717195.